Immunicon Corporation to Introduce Repeat-Free(TM) Poseidon(TM) FISH Probes And Present Workshop and Posters at 2008 AACR Annual Meeting

Immunicon Corporation (NASDAQ-GM:IMMC) will introduce its portfolio of Repeat-Free™ Poseidon™ FISH probes at the Annual Meeting of the American Association for Cancer Research (AACR), the premier educational and scientific event in the oncology research community, April 12-16 at the San Diego Convention Center, San Diego California. In addition, Immunicon will participate in a workshop on circulating tumor cells and present two posters on two new rare cell detection kits based on CellTracks® technology, circulating endothelial cell subsets and circulating melanoma cells. Immunicon will exhibit the Repeat-Free™ Poseidon™ FISH probes and the CellCapture™ CTC Mouse/Rat Kit at booth number 2029. Immunicon believes that Repeat-Free™ technology eliminates the need to use blocking reagents and that RF Poseidon Probes reduces background and provide brighter signals. Most importantly, RF Poseidon Probes need only 4 hours of hybridization time to reach full signal strength, compared to 16 hour hybridization time for traditional probes. Immunicon believes that this workflow improvement combined with assay performance represents clear competitive advantages in the field. The CellCapture™ CTC Mouse/Rat Kit enables pre-clinical studies using circulating tumor cells (CTCs) in animal models. The CellCapture™ Kit uses a manual test procedure to capture CTCs in a few drops of mouse blood and the cells are counted and characterized using the CellTracks® Analyzer II. This kit will enable scientists to conduct efficacy studies in very early drug studies and may streamline this important phase of drug development. The CellCapture™ CTC Mouse Kit and CellTracks® Analyzer II are sold by the Immunicon sales team directly. Workshop: Circulating Tumor Cells Saturday, 1:00 PM-3:00 PM, Room 30A-C, San Diego Convention Center 1:40 PM   Monitoring and characterization of CTC in cancer patients   Leon W.M.M. Terstappen, Immunicon Corporation, Huntingdon Valley, PA   Poster Presentations Sunday, April 13 1:00-5:00 PM Poster Section 12, Abstract #1083, Board 14 Enumeration of VEGFR2 and Ki67 positive subsets of circulating endothelial cells in blood Chandra Rao, Yao Yao, Mark Connelly, Mark Middleton, Gerald Doyle, Leon Terstappen.   Monday, April 14 8:00 AM-12:00 Poster Section 24, Abstract #2174, Board 19 Cytogenetic analysis of Circulating Tumor Cells of metastatic prostate cancer Arjan Gj Tibbe, Joost F. Swenenhuis, Rianne Levink, Ronald CJ Sipkema, Leon WMM Terstappen.   Tuesday, April 15 8:00 AM-12:00 Poster Section 12, Abstract #3695, Board 24 Automated enumeration and characterization of circulating melanoma cells in blood Chandra Rao, Thai Bui, Mark Connelly, Mark Middleton, Gerald Doyle, Leon Terstappen.   Tuesday, April 15 8:00 AM-12:00 Poster Section 12, Abstract #3693, Board 22 Dynamics of circulating tumor cells in mice bearing human breast cancer xenografts Jean-Pierre Eliane, Madeline Repollet, Kathryn E. Luker, Martha Brown, James E. Rae, Gerald V. Doyle, Daniel F. Hayes, Gary D. Luker. Following the conference, the Immunicon presentations will be posted on Immunicon’s Web site at http://www.immunicon.com. For more about the 2008 AACR Annual Meeting, visit http://www.aacr.org/. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com. Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope,” "may,” "believe,” "anticipate,” "plan,” "expect,” "intend,” "assume,” "will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility of Immunicon’s products and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s ability to continue as a going concern; Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company; the risks and uncertainties with the arbitration proceeding with Veridex and the award in favor of Veridex given Immunicon’s dependencies on Veridex; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. "Immunicon,” "CellTracks” and the Immunicon Corporation logo are registered trademarks of Immunivest Corporation, a subsidiary of Immunicon Corporation. Repeat-Free is a trademark of Immunivest Corporation. Poseidon is a trademark of Kreatech Diagnostics. ALL RIGHTS RESERVED.